• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Blogs » The Carlat Psychiatry Blog » Treatment of Bipolar Disorder in Pregnant and Postpartum Women: A Free Review Sheet

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

General Psychiatry / Hospital Psychiatry

Treatment of Bipolar Disorder in Pregnant and Postpartum Women: A Free Review Sheet

June 6, 2026
Victoria Hendrick, MD
PDF

Victoria Hendrick, MD, a clinical professor at the David Geffen School of Medicine at UCLA and is the director of inpatient psychiatry at Olive View—UCLA Medical Center, and Editor-in-Chief of The Carlat Hospital Psychiatry Report.    

Dr. Hendrick has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

WMH_Course_Graphic.png

Treatment of Bipolar Disorder in Pregnant and Postpartum Women | Carlat Psychiatry

Women's Mental Health
Review Sheet Mood Disorders in Pregnancy, Postpartum, and Breastfeeding Module 3

Preconception Management

  • Begin preparation at least six months before conception to ensure stability, switch to safer medications, and manage psychosocial stressors.

Course of Bipolar Disorder During Pregnancy and Postpartum

  • Pregnancy: Low risk period with only about 5% relapse rate.
  • Postpartum: High risk of relapse; about 1 in 3 women with bipolar disorder (BD) relapse.

Predictors of Relapse

  • Early onset of illness, rapid cycling, history of multiple recurrences, and abrupt discontinuation of medications are significant red flags.

Impact on Pregnancy Outcomes

  • Increased risks of substance use, low birth weight, preterm birth, and inadequate prenatal care.

Lithium and Pregnancy

  • Risks: Mainly cardiac anomalies, including Epstein's anomaly. Risk is dose-dependent:
    • No significant increase in risk with a daily dose of 600 mg or less, but risk increases three-fold with a daily dose of over 900 mg
  • Developmental Outcomes in children exposed to lithium in utero appear normal.
  • Management: Use the lowest effective dose, obtain a fetal echocardiogram at week 18–24, and adjust doses carefully throughout pregnancy and postpartum.
    • Obtain lithium levels at least monthly
    • Lithium levels drop up to 34% by third trimester
    • Reduce lithium back to pre-pregnancy dose at delivery to avoid lithium toxicity in the mother

Other Mood Stabilizers

  • Valproate and carbamazepine: High risk of neural tube defects (NTD); avoid in pregnancy.
    • Risk is linked to these medications' antifolate properties, but even high doses of supplemental folate during pregnancy don't reliably prevent the risk of NTD
  • Prenatal valproate is also associated with poor school performance, lower IQ, even autism.
  • Lamotrigine: No significant risk of birth defects, but clearance can increase by 250% during pregnancy, requiring dose increases as necessary for symptom control.

Antipsychotics During Pregnancy

  • There's some evidence of increased rate of birth defects among antipsychotic-exposed infants, but no specific patterns, suggesting that the underlying illness or unidentified confounds might explain this excess risk of birth defects.
  • Risperidone has been linked with an increased risk of cardiac malformations in one study.
  • Keep antipsychotic doses at the lowest effective dose during pregnancy to minimize potential adverse sequelae in newborns like sleepiness, jitteriness and extrapyramidal symptoms.
  • Haloperidol and olanzapine are reasonable options since there's a lot of information on their use in pregnancy; quetiapine is another good option as it has relatively low placental passage.
  • Minimize use of medications for which there's little pregnancy data, like asenapine, paliperidone, lurasidone, clozapine.

ECT

  • Safe, rapid, and effective for patients with bipolar disorder
  • Main complications are preterm labor and transient fetal arrhythmias, but these are rare
  • Produces minimal fetal medication exposure and rapid symptom resolution.

FDA Use in Pregnancy Ratings

  • These have been recently revised and the A, B, C, D, X categories are being phased out.
  • Don't base your choice of medication use in pregnancy solely on FDA use in pregnancy ratings; information from large numbers of human exposures is far more meaningful.

Prophylactic Treatment for Postpartum Psychosis

  • Patients with bipolar disorder should begin prophylactic treatment immediately upon delivery to prevent relapse if they're not already on a mood stabilizer.
  • Lamotrigine and lithium are good options, but careful monitoring and dose adjustments are crucial.

Breastfeeding Considerations

  • Lithium: Generally not recommended due to the potential for high serum levels in nursing infants, especially if the infant experiences dehydration from conditions like diarrhea or fever.
  • Carbamazepine and Valproate: Safe to use in breastfeeding due to their high protein binding.
  • Antipsychotics: Generally considered safe; monitor for dose-dependent exposure risks, like sedation in the baby.
  • Medications' pharmacokinetics: Highly protein-bound medications with short half-lives tend to produce the least infant exposure through breast milk

Summary

Preconception

Begin management early, with a focus on switching to safer medications and stabilizing the patient.

Pregnancy

Monitor closely for signs of relapse, adjust medication doses as needed, and avoid high-risk medications like valproate and carbamazepine. Lithium and lamotrigine levels vary widely as pregnancy progresses. First trimester exposure to lithium increases the risk of cardiac defects in a dose dependent manner.

Postpartum

Implement prophylactic treatment to prevent relapse for patients who are not already on a mood stabilizer.

Breastfeeding

Many medications can be safely taken during breastfeeding, although lithium is best avoided.

Documentation

Carefully document discussions about the risks and benefits of treatment and the patient's capacity to consent. Also, document that you've informed the patient of the 2–4% baseline risk of birth defects, regardless of medication exposures. Indicate whether the patient's symptoms are improving with the medication, and if they are not improving, document that you will discontinue an ineffective medication rather than continue to expose the fetus to the medication.


Mood Disorders in Pregnancy, Postpartum, and Breastfeeding: A Carlat Review Course

Full Review Course & CME

Mood Disorders in Pregnancy, Postpartum, and Breastfeeding: A Carlat Review Course

Victoria Hendrick, MD

Get the full course covering mood disorder management across the perinatal period — including depression, bipolar disorder, and anxiety — with evidence-based guidance on medication safety, breastfeeding, and postpartum risk. CME available.

Get the Course
Try The New AskCarlat AI

Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

Available In The Carlat Toolkit
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2782224449.jpg
    General Psychiatry

    Gender Affirming Care: Fall of the House of Hopkins

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.